8 analysts have shared their evaluations of Johnson & Johnson JNJ during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 3 | 2 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Johnson & Johnson, presenting an average target of $168.25, a high estimate of $181.00, and a low estimate of $153.00. Experiencing a 0.81% decline, the current average is now lower than the previous average price target of $169.62.
Diving into Analyst Ratings: An In-Depth Exploration
The perception of Johnson & Johnson by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Terence Flynn | Morgan Stanley | Raises | Equal-Weight | $171.00 | $169.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $181.00 | $181.00 |
| David Risinger | Leerink Partners | Lowers | Market Perform | $153.00 | $169.00 |
| Matt Miksic | Barclays | Lowers | Equal-Weight | $165.00 | $166.00 |
| Jayson Bedford | Raymond James | Raises | Outperform | $164.00 | $162.00 |
| Terence Flynn | Morgan Stanley | Raises | Equal-Weight | $169.00 | $164.00 |
| Shagun Singh | RBC Capital | Maintains | Outperform | $181.00 | $181.00 |
| Jayson Bedford | Raymond James | Lowers | Outperform | $162.00 | $165.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson & Johnson. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Johnson & Johnson compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Johnson & Johnson's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Johnson & Johnson's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Johnson & Johnson analyst ratings.
Unveiling the Story Behind Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson: Delving into Financials
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Johnson & Johnson displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 2.39%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Johnson & Johnson's net margin is impressive, surpassing industry averages. With a net margin of 50.24%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Johnson & Johnson's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.7% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Johnson & Johnson's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.89%, the company showcases efficient use of assets and strong financial health.
Debt Management: Johnson & Johnson's debt-to-equity ratio is below the industry average at 0.67, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
